ZyVersa Therapeutics Announces That The European Patent Office To Grant Patent Application Covering The Company's Phase 2a-Ready Cholesterol Efflux Mediator VAR 200 For Use In Diabetic Nephropathy/Diabetic Kidney Disease
Portfolio Pulse from Benzinga Newsdesk
ZyVersa Therapeutics announced that the European Patent Office will grant a patent application covering the company's Phase 2a-ready cholesterol efflux mediator VAR 200 for use in diabetic nephropathy/diabetic kidney disease.
June 06, 2023 | 1:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ZyVersa Therapeutics receives patent approval for its Phase 2a-ready cholesterol efflux mediator VAR 200 for use in diabetic kidney disease.
The patent approval for ZyVersa Therapeutics' VAR 200 is a significant milestone for the company, as it provides intellectual property protection and validates the potential of the drug in treating diabetic kidney disease. This news is likely to have a positive impact on the company's stock price in the short term, as it demonstrates progress in the development of their product pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100